Solid Tumor Clinical Trials in Pittsburgh, Pennsylvania

10 studies are recruiting for solid tumor in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

   The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   13 in total

   Run by

   ImmunoGenesis

   See if you can join NCT06014502 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #32, Pittsburgh, Pennsylvania

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

4. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

   Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   41 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04939610 on ClinicalTrials.gov

5. Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

   The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has …

   Stage

   EARLY_Phase 1

   Ages

   Up to 20

   Site

   Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

   Locations

   3 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT05645523 on ClinicalTrials.gov

6. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC, Pittsburgh, Pennsylvania

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

7. Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

   This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   5 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT06171750 on ClinicalTrials.gov

8. Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

   The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, a…

   Stage

   Phase 2

   Ages

   1 to 30

   Site

   Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania

   Locations

   5 in total

   Run by

   Emory University

   See if you can join NCT04469530 on ClinicalTrials.gov

9. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

   This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

   Locations

   9 in total

   Run by

   ImmVira Pharma Co. Ltd

   See if you can join NCT04370587 on ClinicalTrials.gov

10. Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

    The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to targ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Locations

    27 in total

    Run by

    Oxford BioTherapeutics Ltd

    See if you can join NCT04064359 on ClinicalTrials.gov